IGF-1 LR3 IGF
IGF-1 analogue
83-amino-acid IGF-1 analogue with an arginine substitution at position 3, giving low IGF-binding protein affinity and high IGF-1 receptor affinity.
Evidence level. Evidence comes mainly from animal or other preclinical models. About the badges
- Class
- IGF-1 analogue
- Category
- Muscle & Growth Factors
- Type
- Single compound
- Abbreviation
- IGF
- Development and regulatory status
- Not approved for humans; research reagent; WADA-prohibited substance
What researchers study
83-amino-acid analogue of IGF-1 with an arginine substitution at position 3 and an N-terminal extension, giving low affinity for IGF-binding proteins and high affinity for the IGF-1 receptor.
Research areas
- IGF-1 receptor signalling and cell growth
- Recombinant production and bioactivity assays
- Fetal growth and nerve regeneration models
- Anti-doping detection methods
Reported findings
Summaries of published results. Each one is tagged with the type of study behind it. They describe research outcomes and are not claims about any product. Why study type matters.
- sheep
Infused into normal fetal sheep, IGF-1 LR3 increased body weight but lowered insulin concentrations, while in growth-restricted fetuses it did not improve growth
- rodent
In rats with a 1 cm sciatic nerve defect, a conduit with controlled IGF-1 LR3 release improved axonal regeneration, comparable to autologous grafts
- rodent
In a rat detection study, LongR3-IGF-I was undetectable after about 4 h while other IGF-I analogues persisted to 24 h
Studied alongside
Compounds that appear together in research because their mechanisms complement each other, or as comparators. The reasons given are research reasoning, not recommendations for use.
- IGF-DESrelated IGF-1 analogue with reduced binding-protein affinity
- MGFIGF-1 splice-variant peptide studied in muscle repair models
- Somatropin (rHGH)upstream hormone that drives hepatic IGF-1 production
